Therapeutic Targeting of ALK in Neuroblastoma: Experience of Italian Precision Medicine in Pediatric Oncology

SIMPLE SUMMARY: Approximately 50% of high-risk neuroblastomas (NB) relapse within two years after the end of treatment. The prognosis for relapsed or refractory patients is poor, and additional therapeutic options are needed. The identification of ALK somatic mutations or amplification plays an impo...

Descripción completa

Detalles Bibliográficos
Autores principales: Pastorino, Fabio, Capasso, Mario, Brignole, Chiara, Lasorsa, Vito A., Bensa, Veronica, Perri, Patrizia, Cantalupo, Sueva, Giglio, Serena, Provenzi, Massimo, Rabusin, Marco, Pota, Elvira, Cellini, Monica, Tondo, Annalisa, De Ioris, Maria A., Sementa, Angela R., Garaventa, Alberto, Ponzoni, Mirco, Amoroso, Loredana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913103/
https://www.ncbi.nlm.nih.gov/pubmed/36765519
http://dx.doi.org/10.3390/cancers15030560

Ejemplares similares

Ejemplares similares